Behrendt Group

Our major interest is the interplay between cells and their microenvironment in health and disease. We work to understand the interactions between cells and the extracellular matrix and to utilize this understanding to create novel therapeutic options, particularly in cancer treatment. Our particular focus is receptors and proteolytic enzymes that govern the homeostasis and degradation of collagen, the major protein constituent of higher organisms.

The Behrendt Group is located at the Finsen Laboratory, a cancer research department at the Finsen Centre at Rigshospitalet, Copenhagen University Hospital.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

In the media

Our results with tumor targeting have been treated in articles in the Newsletter of the Danish Cancer Society (2015), “Dagens Medicin” (2015) and “Medwatch” (2016). The spin‐out process, moving the ADCendo company into the Creation House program at the BioInnovation Institute, has been taken up in the Newsletter at Sund, University of Copenhagen.